

1 **Title page:**

2 **Exosomes exploit the virus entry machinery and pathway to transmit**  
3 **IFN- $\alpha$ -induced antiviral activity.**

4 Zhenlan Yao<sup>a</sup>, Xiaofang Li<sup>a</sup>, Jieliang Chen<sup>a</sup>, Yunsheng Qiao<sup>a</sup>, Fang Shen<sup>a</sup>, Bisheng Shi<sup>b</sup>,  
5 Jia Liu<sup>a</sup>, Jiahui Ding<sup>a</sup>, Lu Peng<sup>a</sup>, Jianhua Li<sup>a#</sup>, Zhenghong Yuan<sup>a#</sup>

6 <sup>a</sup> Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences,  
7 Shanghai Medical College of Fudan University, Shanghai, China

8 <sup>b</sup> Shanghai Public Health Clinical Center, Shanghai Medical College of Fudan University,  
9 China

10

11 **Running Title: Exosome entry machinery and pathway into hepatocyte.**

12

13 # Address correspondence to Jianhua Li and Zhenghong Yuan, zhyuan@shmu.edu.cn.

14

15 Zhenlan Yao and Xiaofang Li contributed equally to this work.

16

17

18

19

20

21

22

## 23 **Abstract**

24 Interferon- $\alpha$  (IFN- $\alpha$ ) induces the transfer of resistance to hepatitis B virus (HBV) from  
25 liver nonparenchymal cells (LNPCs) to hepatocytes via exosomes. However, little is  
26 known about the entry machinery and pathway involved in the transmission of  
27 IFN- $\alpha$ -induced antiviral activity. Here, we found that macrophage exosomes depend on T  
28 cell immunoglobulin and mucin receptor 1 (TIM-1), a hepatitis A virus (HAV) receptor, to  
29 enter hepatocytes for delivering IFN- $\alpha$ -induced anti-HBV activity. Moreover, two primary  
30 endocytic routes for virus infection, clathrin-mediated endocytosis (CME) and  
31 macropinocytosis, collaborate to permit exosome entry and anti-HBV activity transfer.  
32 Subsequently, lysobisphosphatidic acid (LBPA), an anionic lipid closely related to  
33 endosome penetration of virus, facilitates membrane fusion of exosomes in late  
34 endosomes/ multivesicular bodies (LEs/MVBs) and the accompanying exosomal cargo  
35 uncoating. Together, this study provides comprehensive insights into the transmission  
36 route of macrophage exosomes to efficiently deliver IFN- $\alpha$ -induced anti-HBV activity and  
37 highlights the similarities between the entry mechanisms of exosomes and virus.

38

## 39 **Importance**

40 Our previous study showed that LNPC-derived exosomes could transmit IFN- $\alpha$ -induced  
41 antiviral activity to HBV replicating hepatocytes, but the concrete transmission  
42 mechanisms which include exosome entry and exosomal cargo release remain unclear.  
43 In this study, we found that virus entry machinery and pathway were also applied to

44 exosome-mediated cell-to-cell antiviral activity transfer. Macrophage-derived exosomes  
45 exploit hepatitis A virus receptor for access to hepatocytes. Later, CME and  
46 macropinocytosis are utilized by exosomes which is followed by exosome-endosome  
47 fusion for efficient transfer of IFN- $\alpha$ -induced anti-HBV activity. Dissecting the similarities  
48 between exosome and virus entry will be beneficial to designing exosomes as efficient  
49 vehicles for antiviral therapy.  
50

## 51 Introduction

52 Hepatitis B virus (HBV) is a small, enveloped DNA virus that replicates via an RNA  
53 intermediate and belongs to the Hepadnaviridae family(1). Approximately 400 million  
54 people are chronically infected with HBV worldwide(2). Chronic HBV infection is a major  
55 risk factor for the development of liver cirrhosis and hepatocellular carcinoma(3).  
56 Interferon (IFN)- $\alpha$  is licensed for the treatment of HBV chronic infection, with a response  
57 rate of 30-40% and a clinical cure rate of approximately 10%(4), but its efficacy is limited  
58 in hepatocytes (5, 6). We and others previously reported that IFN- $\alpha$  induced the transfer  
59 of resistance to hepatitis viruses from nonpermissive liver nonparenchymal cells  
60 (LNPCs), including liver resident macrophages, to permissive hepatocytes via exosomes,  
61 but the underlying mechanism remains largely unclear(7-11).

62 Exosomes are 40–100 nm membrane vesicles derived from the intraluminal  
63 vesicles (ILVs) of multivesicular bodies (MVBs) that are secreted into the extracellular  
64 milieu through the fusion of MVBs with the plasma membrane(12, 13). These vesicles  
65 can serve as mediators of intercellular communication to exchange functional proteins,  
66 lipids, mRNAs and microRNAs (miRNAs) among cells(14-16). Given the emerging roles  
67 of exosomes from IFN- $\alpha$ -induced LNPCs in the antiviral innate response and their  
68 therapeutic potential(7, 8, 17, 18), it is important to understand the molecular  
69 mechanisms by which nonparenchymal cell-derived exosomes are taken up into  
70 hepatocytes and release their cargo to inhibit HBV replication.

71 The entry strategy used by a given exosome may depend on the proteins and lipids on  
72 the surfaces of both exosomes and recipient cells(19-21). The routes and fates of

73 exosome internalization may partially overlap with those of the virus(9, 22, 23). Here, we  
74 found that the hepatitis A virus receptor, TIM-1, mediated the internalization of  
75 macrophage-derived exosomes into hepatocytes; we showed that the rapid  
76 clathrin-dependent pathway in concert with sustained macropinocytosis, two primary  
77 pathways for virus invasion, were also used as the major endocytic routes for exosome  
78 entry and the transmission of IFN- $\alpha$ -induced HBV resistance. After internalization,  
79 membrane fusion of exosomes and accompanying exosomal cargo uncoating took place  
80 in LEs/MVBs, relying on the LE-specific anionic lipid lysobisphosphatidic acid (LBPA).  
81 Collectively, our findings demonstrate that macrophage exosomes require virus entry  
82 machinery and pathway for transmission of IFN- $\alpha$ -induced antiviral activity to combat  
83 HBV in hepatocytes.

## 84 **Materials and methods**

### 85 **Antibodies, reagents and Chemical Inhibitors**

86 Antibodies for LAMP-2 (sc-18822), EEA1 (sc-33585) and normal mouse IgG  
87 (sc-2025) were purchased from Santa Cruz Biotechnology. Antibodies for Alix  
88 (12422-1-AP), TSG101 (14497-1-AP), CD63 (25682-1-AP), RAB5 (11947-1-AP) and  
89 RAB7 (55469-1-AP) were purchased from Proteintech Group (Rosemont, USA).  
90 Antibody for clathrin heavy chain (ab21679) was from Abcam (Cambridge, USA).  
91 Antibodies for  $\beta$ -actin (A2228) and GFP (G6539) were from Sigma-Aldrich. Antibody for  
92 LBPA (MABT837) was from EMD Millipore (Billerica, USA). Fluorescent secondary  
93 antibodies (A11001, A10523) were purchased from Invitrogen. Annexin V -FITC

94 (640905) was purchased from Biolegend (San Diego, USA). Phalloidin-iFluor 488 (23115)  
95 was from AAT Bioquest (Sunnyvale, USA). Fc-TIM-1-His, a protein of TIM-1 extracellular  
96 domain (AAC39862.1) (Ser 21-Gly 290) which is fused with a polyhistidine tag at the  
97 C-terminus and the Fc region of human IgG1 at the N-terminus was from Sino Biological  
98 (Beijing, China). Aldehyde/Sulfate Latex Beads(4% w/v, 4  $\mu$ m) was from Invitrogen  
99 (Carlsbad, USA).

100 Chemical inhibitors including dynasore (D7693), M $\beta$ CD (C4555), EIPA (A3085),  
101 IPA-3 (I2285) and rottlerin (R5648) were from Sigma-Aldrich. Filipin III (70440) was  
102 purchased from Cayman chemical (Ann Arbor, USA). Chlorpromazine (S2456) and  
103 nystatin (S1934) were purchased from Selleck Chemicals (Houston, USA).

#### 104 **Cells, plasmids, siRNAs and transfection**

105 The HepG2.2.15, HepG2 and THP-1 cells used in this study have been described  
106 previously(7, 24). HepG2.2.15 and HepG2 cells were cultured in DMEM with 10% fetal  
107 bovine serum (FBS) (Biologic Industries, Beit Haemek, Israel) and  
108 Penicillin-Streptomycin (Invitrogen, Carlsbad, USA), while THP-1 cells were maintained  
109 in RPMI-1640 with 10% FBS and antibiotics. To obtain macrophage-like cells that closely  
110 resembled human monocyte-derived macrophages, THP-1 cells were differentiated via  
111 PMA stimulation (phorbol 12-myristate 13-acetate; Sigma-Aldrich, Taufkirchen,  
112 Germany), as described previously(7, 25).

113 Markers of endosomal compartments fused with cyan fluorescent protein (CFP),  
114 including CFP-RAB5, CFP-RAB7 and CFP-CD63, were kindly provided by Walther  
115 Mothes from Yale University in New Haven, CT, USA(26). K44A dynamin-2 pEGFP was

116 a gift from Sandra Schmid (Addgene plasmid # 34687). pcDNA3-EGFP-Cdc42-T17N  
117 (Addgene plasmid # 12976) and pcDNA3-EGFP-Rac1-T17N (Addgene plasmid # 12982)  
118 were gifts from Gary Bokoch. Caveolin-1 labeled with C-terminal tag of enhanced green  
119 fluorescent protein (EGFP) was constructed by insertion of the caveolin-1 cDNA  
120 fragment into a pEGFP-N1 expression vector (Clontech, Palo Alto, USA). To produce  
121 GFP-carrying exosomes, a THP-1 cell line stably expressing GFP was established via  
122 lentivirus transduction. The lentiviral vector PLJM1-GFP (Addgene) was used to  
123 generate lentivirus for the transduction, according to the manufacturer's instructions  
124 (Addgene). Stable GFP-expressing THP-1 cells were selected by flow cytometric sorting  
125 (BD FACSAria II; BD Biosciences, San Jose, USA). siRNAs for clathrin heavy chain,  
126 caveolin-1 and negative control were purchased from Santa Cruz Biotechnology. siRNA  
127 for TIM-1 was purchased from Ruibo.

128 DNA plasmid transfection into HepG2 cells was performed using Lipofectamine  
129 2000 (Invitrogen). For RNA-mediated interference, HepG2 cells at 30 to 40% confluence  
130 were transfected with 50 nM small interfering RNA (siRNA) duplexes designed and  
131 purchased from Santa Cruz (Dallas, USA) or Ruibo (Guangzhou, China) using  
132 RNAiMAX (Invitrogen) according to the manufacturer's instructions. At 24 h  
133 post-transfection, the cells were transfected again with 50 nM of the same siRNA  
134 duplexes. The following treatment was performed 72 h after the first siRNA transfection.

### 135 **Exosome purification, characterization and labeling**

136 Macrophages derived from THP-1 or GFP-expressing THP-1 cells were grown in  
137 culture medium supplemented with 10% FBS (which was depleted of endogenous

138 exosomes by overnight centrifugation at 100,000 g). Exosomes from the culture  
139 supernatants were isolated by differential centrifugation, as described previously(7). To  
140 obtain exosomes from IFN- $\alpha$ -treated macrophages, the macrophages were treated for  
141 48 h with 1,000 U/ml of IFN- $\alpha$  (PBL Assay Science, New Brunswick, USA) before  
142 isolation. The purified exosomes were characterized via electron microscopy and  
143 immunoblot analysis, as described previously(7). Protein amounts of exosomes were  
144 quantified using a BCA protein assay kit (Pierce, Rockford, USA).

145 The isolated exosomes were labeled with PKH67 or PKH26 according to the  
146 manufacturer's protocol (Sigma-Aldrich) for use in endocytosis assays. For the  
147 fluorescence self-quenching assay for membrane fusion, R18 (Octadecyl Rhodamine B  
148 Chloride, Invitrogen) was inserted into the viral membranes at a self-quenching surface  
149 density(27, 28).

#### 150 **Endocytosis assays of exosomes**

151 To assay exosome internalization, 10-20  $\mu$ g/ml of labeled exosomes were added to  
152 HepG2 cells cultured with serum-free medium and incubated at 37°C. HepG2 cells were  
153 untreated or pretreated with the indicated amounts of inhibitors for 30 min before  
154 incubation with exosomes or endocytic markers. Except cholesterol inhibitors (M $\beta$ CD,  
155 nystatin, and filipin III), inhibitory compounds were present continuously during  
156 subsequent endocytosis assays. Despite moderate cytotoxicity of M $\beta$ CD-treated cells,  
157 no significant toxicity was observed for the other inhibitors (data not shown), which  
158 indicated that inhibition of exosome internalization was not caused by cytotoxicity. As  
159 controls, HepG2 cells were incubated with 2  $\mu$ g/ml of Alexa568-transferrin (Invitrogen) or



160 0.2 mg/ml of dextran labeled with Rhodamine B isothiocyanate (RhoB-dextran,  
161 Sigma-Aldrich) for 30 min or 1 h at 37°C. For competitive inhibition of TIM-1-mediated  
162 exosome entry by Fc-TIM-1-His, HepG2 cells were incubated with labeled exosomes in  
163 presence of 1 µg/ml Fc-TIM-1-His at 37°C for 2 h. Endocytosis was stopped, and  
164 surface-bound exosomes or markers were removed by washing with ice-cold PBS.

### 165 **Confocal laser-scanning and time-lapse microscopy**

166 Confocal images were captured using a Leica TCS SP8 confocal microscope (Leica  
167 Microsystems, Buffalo Grove, USA) with a 400X or 630X oil objective (pinhole set at 1  
168 Airy unit) and processed using LAS X (Leica). For time-lapse microscopy analysis,  
169 HepG2 cells were grown in 35-mm glass bottom culture dishes with four chambers  
170 (Cellvis, Mountain View, USA) overnight. Before microscopic examination, the medium  
171 was changed to serum-free DMEM, and fluorescence-labeled exosomes were added  
172 and kept in the medium during image collection. Time-lapse images were captured every  
173 10 min for 6-µm slices using a DeltaVision Elite high-resolution microscope (Applied  
174 Precision, Issaquah, USA) connected to a 37°C incubator and buffered with 5% CO<sub>2</sub>.  
175 The images were further processed with softWoRx Explorer (Applied Precision,  
176 Issaquah, USA) and analyzed with ImageJ (NIH, USA). For colocalization studies, the  
177 distribution patterns of the fluorescent signals were analyzed using the Plot Profile  
178 analysis tool of ImageJ, and Pearson's correlation coefficients (Rr) were obtained by  
179 using the Colocalization finder plugin of ImageJ. For the Pearson's correlation  
180 coefficients (Rr), the values ranged from 1 (a perfect positive correlation) to -1 (a perfect  
181 negative correlation), with 0 representing a random distribution(29). Time-related

182 fluorescence intensities of the R18 dequenching signals were assessed using the Time  
183 Series Analyzer V3 plugin of ImageJ.

#### 184 **Flow cytometry analysis**

185 For endocytosis assay, cells were washed three times with ice-cold PBS, detached  
186 using trypsin, and subsequently resuspended in PBS with 1% FBS. Flow cytometry  
187 analysis was performed on an LSR Fortessa instrument integrated with the FACSDiva  
188 software (BD Biosciences). A minimum of 10,000 events within the gated live cells were  
189 collected and analyzed per sample using FlowJo (Tree Star, Ashland, USA).

190 For PtdSer detection, 4  $\mu$ m latex beads were coated with exosomes through 2-hour  
191 incubation at room temperature. The exosome-bead complexes were then blocked with  
192 200 mM glycine and normal IgG and washed with 1% FBS which was followed by  
193 annexin V-FITC labeling for 40 min at 4°C. The exosome-bead complexes were  
194 subsequently washed and suspended with 1% FBS for flow cytometry analysis. A  
195 minimum of 50,000 events within the gated exosome-bead complexes were collected  
196 and analyzed per sample via FlowJo.

#### 197 **HBV DNA quantitation and antigen measurement**

198 HepG2.2.15 cells pre-transfected with siRNAs or pretreated with chemical inhibitors  
199 were incubated with exosomes isolated from macrophages with or without IFN- $\alpha$   
200 treatment at a concentration of 10  $\mu$ g/ml for 48 h. The supernatant of the HepG2.2.15  
201 culture was collected and transferred for viral antigen measurement using the  
202 enzyme-linked immunosorbent assay (Kehua ELISA kit; Kehua, Shanghai, China). HBV  
203 DNA levels in the culture medium were extracted using a MagNA Pure 96 system (Roche,

204 Shanghai, China) and quantified using real-time PCR.

205 **Statistics**

206 All data are presented as the mean of duplicates  $\pm$  S.D. Statistical comparisons

207 were made using a two-tailed Student's t-test; *P* values of 0.05 or less were considered

208 to be statistically significant.

209

210

## 211 **Results**

### 212 **PtdSer receptor TIM-1 is necessary for exosome entry and the transfer of** 213 **IFN- $\alpha$ -induced anti-HBV activity**

214 Exosomes were isolated from the culture of THP-1-derived macrophages by  
215 differential centrifugation, as described previously(7). Membrane vesicles approximately  
216 100 nm in diameter with a cup-shaped structure typical of exosomes were identified by  
217 electron microscopy (Fig. 1A). Further characterization by immunoblotting indicated the  
218 presence of exosomal markers (CD63, TSG101, and Alix), conserved exosomal proteins  
219 (LAMP-2,  $\beta$ -actin) and the absence of the endosomal marker EEA1 (Fig. 1B). Isolated  
220 exosomes were labeled with the fluorescent lipid dye PKH26 or PKH67. We observed  
221 the internalization of PKH26-labeled exosomes by hepatocyte-derived HepG2 cells,  
222 which were stained for cytoskeletal F-actin with Phalloidin-iFluor 488 (Fig. 1C) at 37°C,  
223 and found that the uptake kinetics were time- and concentration-dependent (Fig. 1D).

224 PtdSer — an apoptosis marker typically located on the inner leaflet of the plasma  
225 membrane — is found on the outer membrane of exosomes from bone marrow derived  
226 dendritic cells (BMDCs) and oligodendrocytes(20, 30). Previous experimental evidence  
227 indicates that some viruses may exploit PtdSer as apoptotic disguise and enter target  
228 cells through PtdSer receptor-mediated internalization(31). To determine whether and  
229 which PtdSer receptors play a role in the entry of macrophage-derived exosomes into  
230 hepatocytes, we first confirmed PtdSer expression on the outer membrane of

231 macrophage-derived exosomes through annexin-V labeling of exosomes isolated from  
232 macrophages (Fig. 1 E).

233 We then inhibited the expression of two hepatic PtdSer receptors involved in virus  
234 entry(31), T cell immunoglobulin and mucin receptor 1 (TIM-1) (Fig. 1F) and Growth  
235 Arrest Specific 6 (GAS6) (data not shown), in HepG2 cells with specific siRNAs. The  
236 uptake of PKH26-labeled exosomes was significantly reduced in HepG2 cells after TIM-1  
237 knockdown (Fig. 1G and H), but interference via GAS6 expression had no effect on  
238 exosome uptake (data not shown). It is notable that the IgV in ectodomains of TIM  
239 proteins bind PtdSer on viral envelope and enhance virus entry(32). Exogenous  
240 Fc-TIM-1-His, TIM-1 extracellular domain fused with His tag and Fc region of human  
241 IgG1, competitively inhibited exosome internalization by HepG2 cells (Figure 1I), which  
242 suggested that the ectodomain of TIM-1 also play a functional role in exosome entry.  
243 Corresponding to previous results reflecting the engagement of TIM-1 in exosome  
244 uptake, IFN- $\alpha$ -induced anti-HBV activity mediated by exosomes from IFN- $\alpha$ -stimulated  
245 macrophages (IFN-EXO) was diminished in TIM-1-knockdown HepG2.215 cells in  
246 comparison to that in cells transfected with control (ctrl) siRNA, as indicated by HBsAg  
247 expression (Fig. 1J). In addition, IFN- $\alpha$ -induced exosome-mediated antiviral activity only  
248 slightly suppressed HBV DNA production in the supernatant of TIM-1-knockdown cells,  
249 in contrast to cells transfected with ctrl siRNA (Fig. 1K). It was unexpected that the  
250 knockdown of TIM-1 caused a decrease in HBV DNA in the supernatant, which suggests  
251 that TIM-1 is a positive factor for HBV replication (Fig. 1K). Collectively, these findings  
252 demonstrated that PtdSer and its receptor TIM-1 act as portals for exosomal

253 internalization and the transfer of IFN- $\alpha$ -induced antiviral activity against HBV.

254

## 255 **Dynamin-2 and cholesterol are required for exosome entry into hepatocytes**

256 The interaction of exosomes with receptors on donor cells can induce the cellular  
257 response of internalization through endocytic pathways(33). Endocytosis occurs via  
258 several pinocytic mechanisms that include the clathrin-mediated mechanism,  
259 macropinocytosis, the caveolae-mediated mechanism and other less well-defined  
260 mechanisms(34, 35). The large GTPase dynamin-2 functions at the heart of endocytic  
261 vesicle fission in clathrin-mediated endocytosis (CME) and caveolae-mediated  
262 endocytosis (Fig. 2A)(36). Recent studies showed that dynamin is also responsible for  
263 the closure of circular ruffles in macropinocytosis (Fig. 2A)(37). Cholesterol plays  
264 essential roles in the formation of caveolae, clathrin-coated pit budding and membrane  
265 ruffling in macropinocytosis (Fig. 2A)(38-40).

266 To investigate the role of dynamin-2 in exosome entry, we suppressed the function  
267 of dynamin-2 in HepG2 cells with the specific inhibitor dynasore. The efficacy of  
268 dynasore was confirmed using Alexa568-labeled transferrin (Alexa568-TFN), which is  
269 the best-characterized cargo protein of CME (Fig. 2B and C). The uptake of  
270 PKH26-labeled exosomes was reduced by approximately 60% following dynasore  
271 treatment (Fig. 2C). In addition, the expression of the dominant-negative mutant of  
272 dynamin-2, Dyn2K44A, also significantly blocked exosome entry (Fig. 2D). We next  
273 sought to determine whether cholesterol is necessary for exosome entry into  
274 hepatocytes. Using Methyl- $\beta$ -cyclodextran (M $\beta$ CD) to extract cholesterol from the

275 plasma membrane of HepG2 cells significantly inhibited PKH26-labeled exosome entry  
276 (Fig. 2E and F). The reduction was up to 86% when treating HepG2 cells with 10 mM  
277 M $\beta$ CD (Fig. 2 F). Masking cholesterol with binding compounds (nystatin and filipin)  
278 resulted in milder but still apparent inhibition of exosome uptake by HepG2 cells (Fig. 2E,  
279 G and H). These results indicated that the dynamin-2- and cholesterol-dependent  
280 endocytic pathways are required for the entry of exosomes into hepatocytes.

281

282 **Clathrin- but not caveolae-mediated endocytosis is important for exosome uptake**  
283 **and the transmission of IFN- $\alpha$ -induced anti-HBV activity**

284 CME, which is the uptake of material into cells from the surface using  
285 clathrin-coated vesicles, is the preferred route by which some PtdSer-exposing viruses  
286 enter target cells(31). To investigate the dependence of exosome entry on CME,  
287 hepatocytes were treated with chlorpromazine (CPZ), an inhibitor of clathrin-coated pit  
288 assembly. PKH26-labeled exosome uptake decreased by 34%, and as a positive control,  
289 transferrin uptake was inhibited under the same conditions (Fig. 3A and B). Moreover,  
290 knockdown of the clathrin heavy chain (CHC) also reduced exosome entry into  
291 hepatocytes by 34% (Fig. 3C and D). To further investigate the endocytic pattern  
292 engaged in exosome entry, exosomes were stained with PKH67 and administered to  
293 HepG2 cells in the presence of Alexa568-TFN. Partial colocalization of exosomes and  
294 transferrin was observed 30 min post-internalization, while little colocalization was  
295 captured 1 h after internalization, indicating rapid clathrin-dependent endocytosis during  
296 the early stage of exosome internalization (Fig. 3E and F). Scatterplots, Pearson's

297 correlation coefficient ( $R_r$ ) and an intensity profile were used to quantify the degree of  
298 colocalization between PKH67-labeled exosomes and Alexa568-TFN. Partial  
299 colocalization between exosomes and transferrin was evidenced by scatterplots, a  
300 fraction of which were close to diagonal, and the corresponding  $R_r$  was 0.1292 (see  
301 Materials and Methods) (Fig. 3E). There were several peak superpositions in the  
302 intensity profile (Fig. 3E). Correspondingly, the downregulation of CHC expression in  
303 HBV-replicating hepatocytes weakened the IFN- $\alpha$ -induced anti-HBV activity transmitted  
304 by exosomes in HepG2.2.15 cells, as indicated by viral antigen expression and DNA  
305 quantification (Fig. 3G and H). In addition, caveolae-mediated endocytosis did not  
306 appear to be required for exosome internalization by hepatocytes, as indicated by the  
307 inhibition of caveolin-1 (CAV1) expression (Fig. 3I and J). Together, these data showed  
308 that clathrin- but not caveolae-mediated endocytosis contributed to exosome uptake and  
309 the transfer of IFN- $\alpha$ -induced HBV resistance.

310

### 311 **Macropinocytosis plays an alternative role in exosome uptake and the transfer of** 312 **IFN- $\alpha$ -induced anti-HBV activity**

313 More than one endocytic route was reported to be used in virus or exosome  
314 entry(33, 41). Given the incomplete inhibition of exosome entry by blockade of CME and  
315 the sustained increase of internalized exosomes for hours (Fig. 1D and 3B, D), there  
316 might be alternative pathways to support exosome entry into hepatocytes.  
317 Macropinocytosis is a fluid-phase type of endocytosis that is accompanied by membrane  
318 ruffles regulated by actin rearrangement(37). This process is engaged in apoptotic cell



319 removal and is favored by some viruses that use apoptotic mimicry to enter target  
320 cells(31).

321 The induction of a robust increase in fluid-phase uptake is a hallmark of  
322 macropinocytosis(39). The results showed that the uptake of 70-kDa dextran labeled  
323 with Rhodamine B isothiocyanate (RhoB-dextran), which is a fluid-phase marker specific  
324 for macropinocytosis, was enhanced by incubation with macrophage-derived exosomes  
325 in HepG2 cells (Fig. 4A). A Na<sup>+</sup>/H<sup>+</sup> exchanger (NHE) is needed for macropinosome  
326 formation via the modulation of Rho GTPases at the plasma membrane, and NHE  
327 inhibition by 5-(N-Ethyl-N-isopropyl) amiloride (EIPA) has been widely used as a  
328 diagnostic criterion for macropinocytosis(42). The entry of both exosomes and dextran  
329 into HepG2 cells was apparently inhibited by EIPA, and a remarkable decrease (80%) in  
330 exosome uptake was achieved in the presence of 80 nM EIPA (Fig. 4B and C). PAK1 and  
331 PKC are two serine/threonine kinases that are required for macropinocytosis(39). We  
332 found that exosome entry was markedly blocked by the PAK1 inhibitor IPA-3 and the  
333 PKC inhibitor rottlerin (Fig. 4D-F). PKC inhibition resulted in a more significant reduction  
334 in exosome internalization by up to 66% in hepatocytes (Fig. 4F). As a positive control,  
335 dextran internalization was greatly inhibited by the two kinase inhibitors (Fig. 4 D-F).  
336 However, the expression of a dominant-negative mutant of Rac1 or Cdc42, two common  
337 GTPases that modulate membrane ruffles, had no effect on exosome internalization (Fig.  
338 4G and H), which suggested that macrophage exosomes might enter hepatocytes via a  
339 Rac1- or Cdc42-independent route. Next, we reinvestigated the role of macropinocytosis  
340 in exosome entry by comparing the distribution patterns of dextran and exosomes after

341 internalization. In contrast to that seen for rapid CME-dependent exosome uptake,  
342 confocal images showed consistent colocalization of PKH67-labeled exosomes with  
343 RhoB-dextran-filled intracellular vacuoles (Fig. 4I and J). A highly overlapped distribution  
344 was observed 1 h post-exosome internalization and was confirmed by the corresponding  
345 scatterplots, colocalization coefficient and intensity profile (Fig. 4J). Furthermore, the  
346 inhibition of macropinocytosis in HepG2.2.15 cells by EIPA partially blocked the  
347 IFN- $\alpha$ -induced anti-HBV activity mediated by exosomes derived from IFN-treated  
348 macrophages, as indicated by viral DNA quantification (Fig. 4K). Thus, we concluded  
349 that macropinocytosis served as a sustained alternative route that was active from the  
350 early stage of exosome internalization and cooperated with CME to ensure hepatocytes  
351 the access to exosome-mediated HBV resistance.

352

353 **Exosomes expose cargo through membrane fusion in late endosomes/  
354 multivesicular bodies**

355 Once internalized within primary endocytic vesicles, the incoming substances  
356 traffic into the endosomal system(41). The endocytosed substances are routed from  
357 early endosomes (EEs) to late endosomes (LEs, often taking the form of MVBs) and  
358 lysosomes for degradation(41). Membrane fusion-induced endosome penetration is  
359 commonly manipulated by viruses or delivery vectors to send viral genomes or biologics  
360 to the cytosol before lysosomal degradation(27, 43-45). It remains unknown whether a  
361 similar membrane fusion strategy is adopted for exosomal cargo release in endosomes  
362 after internalization (Fig. 5A).

363 We first used time-lapse microscopy to track membrane fusion events in live  
364 hepatocytes incubated with macrophage-derived exosomes prelabeled with  
365 self-quenching amounts of the hydrophobic dye rhodamine C18 (R18). R18 is commonly  
366 used as a fluorescent probe to detect virus-induced membrane fusion. The probe is  
367 incorporated into membranes at high concentrations to cause self-quenching, and  
368 dequenching of the probe occurs when membrane fusion decreases in density(27, 28).  
369 The dequenching signal of membrane fusion was first captured approximately 45  
370 minutes after treating HepG2 cells with R18-labeled exosomes, and fusion events  
371 followed within 1 hour (Fig. 5B). The fluorescence intensity profile showed persistent  
372 enhanced R18 fluorescence for the fusion spots (Fig. 5C).

373 EEs and LEs/MVBs are major fusion sites for some viruses to deliver  
374 nucleocapsids and release nucleocapsids to the cytosol(46). To locate the exact site at  
375 which membrane fusion occurred after exosome internalization, we performed  
376 colocalization experiments using a variety of endosomal markers. Endosomal  
377 compartments in HepG2 cells were labeled via transient transfection of plasmids  
378 encoding CFP-fused markers for EEs (RAB5), LEs/MVBs (RAB7) and intraluminal  
379 vesicles (ILVs) in MVBs (CD63). The dequenching signal of membrane fusion was  
380 colocalized with the LE marker CFP-RAB7 and the ILV marker CFP-CD63 in live HepG2  
381 cells after treatment with R18-labeled exosomes, while no colocalization was observed  
382 with markers for EEs (CFP-RAB5) (Fig. 5D). Hence, LEs/MVBs might be the proper site  
383 for the membrane fusion of macrophage-derived exosomes after exosome  
384 internalization.

385 To track exosomal cargo after membrane fusion, the live dynamics of exosomal  
386 cargo in hepatocytes were tested by monitoring the membrane fusion events of  
387 R18-labeled GFP-carrying exosomes using time-lapse microscopy, with exosomes  
388 isolated from GFP-expressing macrophages. At the beginning of the experiment, orange  
389 fluorescence was observed at the fusion site due to the combined fluorescence emitted  
390 by dequenching R18 inserted into exosome membranes and GFP encapsulated in  
391 exosomes. As fusion proceeded, the extreme dilution of the R18-labeled membrane  
392 components increased the fluorescence of the gradually exposed GFP. A complete color  
393 switch was accomplished when the exosomal cargo GFP was totally uncoated and  
394 “released” (Fig. 5E). In addition, confocal images proved again that LEs were the site of  
395 membrane fusion for GFP-carrying exosomes (Fig. 5F). The colocalization coefficient of  
396 R18 and GFP was approximately 0.9 in HepG2 cells, indicating a high frequency of  
397 fusion events among internalized exosomes. Together, these data indicated that  
398 LEs/MVBs provided the proper conditions for exosome fusion and cargo uncoating,  
399 which might promote exosomal cargo release based on endosome penetration.

400

#### 401 **Lysobisphosphatidic acid (LBPA) contributes to exosome fusion and the** 402 **uncoating of exosomal cargo**

403 Anionic lipids are beneficial for endosome penetration(46). A high concentration of  
404 anionic lipids makes LEs a suitable location for endosome leakage via membrane fusion.  
405 Notably, the LE-specific anionic lipid LBPA assists as both viruses and delivery vectors to  
406 achieve efficient cytosolic access via membrane fusion-induced endosome

407 penetration(43-48).

408 The accumulation of PKH26-labeled exosomes in the LBPA-rich structure  
409 suggested a potential interaction between the two components (Fig. 6A). Partial  
410 colocalization between the dequenching R18 of exosomes and LBPA signals indicated  
411 the participation of LBPA in the membrane fusion of exosomes in LEs/MVBs (Fig. 6B). To  
412 verify the dependence of exosome fusion on LBPA, HepG2 cells were pre-incubated with  
413 an anti-LBPA blocking antibody(27, 43), and the dequenching signals of R18-labeled  
414 exosomes were tracked via time-lapse microscopy. Pretreatment with an anti-LBPA  
415 blocking antibody produced significant inhibition of membrane fusion, as suggested by  
416 the decayed R18 dequenching of exosomes (Fig. 6C). The fluorescent intensity profile of  
417 tracked fluorescent puncta further manifested the dependence of exosome fusion on  
418 LBPA (Fig. 6D). To inquire into the contribution of LBPA to the potential intracellular  
419 release of exosomal cargo before lysosomal degradation, we incubated LBPA-blocked  
420 HepG2 cells with GFP-carrying exosomes and judged the delivery efficiency of exosomal  
421 cargo to lysosomes based on the colocalization efficiency between GFP and lysosomes.  
422 The incidence of colocalization increased significantly in cells pretreated with the  
423 anti-LBPA blocking antibody, as indicated by the 2-fold increase in the colocalization  
424 coefficient (0.5487) in comparison to control cells (Fig. 6E). This finding suggested that  
425 some exosomal cargo might escape from endosomes to avoid lysosomal degradation  
426 via LBPA-dependent membrane fusion in LEs/MVBs. Unfortunately, the blocking of LBPA  
427 in HepG2.2.15 cells led to a four-fold increase in HBV DNA in the supernatant,  
428 suggesting that LBPA is closely related to HBV replication (Fig. 6F). This outcome

429 impeded further investigations of LBPA in exosome-mediated antiviral activity  
430 transmission. Taken together, LBPA is very important for exosome fusion and the  
431 uncoating of exosomal cargo.

432

## 433 **Discussion**

434 In this report, we demonstrate that macrophage-derived exosomes utilize virus entry  
435 machinery and pathway to proffer IFN- $\alpha$ -induced HBV resistance to hepatocytes. We  
436 have presented evidence that macrophage exosomes engage TIM-1, a PtdSer receptor,  
437 to enter hepatocytes and undergo rapid CME or sustained macropinocytosis. Our data  
438 also suggest that LEs/MVBs are the primary location for LBPA-mediated exosome fusion  
439 and accompanying exosomal cargo uncoating for potential intracellular release. The  
440 endocytic pathway and membrane fusion in endosomes provide an ideal strategy for  
441 exosomes from IFN- $\alpha$ -induced macrophages to deliver antiviral activity and control HBV  
442 replication in hepatocytes (Fig. 7).

443 Exosomes have been shown to interact with membrane receptors on target cells to  
444 facilitate subsequent endocytosis(33). Recently, a virus endocytic model – apoptotic  
445 mimicry – was suggested to play a role in exosome entry(9, 31). As former ILVs form by  
446 inward budding of the LE/MVB-limiting membrane, exosomes are thought to expose  
447 PtdSer, an apoptotic marker, on the external leaflet of the membrane and initiate PtdSer  
448 receptor-engaged uptake(49). Apoptotic mimicry has been used by hepatotropic  
449 hepatitis A virus (HAV) for infection, in which the virus is cloaked in a PtdSer-containing

450 envelope by hijacking the exosome secretion pathway and entering target cells via  
451 TIM-1-mediated internalization(31, 50, 51). In this study, we verified PtdSer expression  
452 on the external membrane of macrophage exosomes and found that the knockdown of  
453 TIM-1 significantly blocked exosome entry and the transfer of IFN- $\alpha$ -induced HBV  
454 resistance into hepatocytes. These results indicate that macrophage exosomes may  
455 exploit an endocytic strategy similar to apoptotic mimicry as HAV uses to enter cells via  
456 TIM-1-mediated internalization. However, the possibility is not excluded that additional  
457 receptors may act as co-factors to enhance the attachment of exosomes onto  
458 hepatocytes for subsequent entry. Several adhesion molecules enriched on exosome  
459 surface, including integrins, immunoglobulins and proteoglycans, are reported to be  
460 involved in exosome attachment to cells(9, 21, 33), which implies the necessity of further  
461 study on co-receptors.

462 Adhesion to receptors commonly results in a cellular response of internalization  
463 through endocytic pathways(41). Experimental evidence implies important roles for  
464 various endocytic pathways in exosome entry, including CME, caveolae-mediated  
465 endocytosis, macropinocytosis and phagocytosis(22, 23, 30, 33). It is believed that  
466 various combinations of endocytic mechanisms are responsible for exosome entry in  
467 different cell types(33). PtdSer exposure is exploited by some viruses as apoptotic  
468 disguise which triggers subsequent CME or macropinocytosis for virus entry(31).

469 According to the results, macrophage exosome entry is sensitive to dynamin and  
470 cholesterol inhibitors. Dynamin mediates the fission of endocytic vesicles from the  
471 plasma membrane in several endocytic mechanisms, such as CME and

472 caveolae-mediated endocytosis(36). Recent research indicates that dynamin also  
473 regulates the closure of circular ruffles during macropinocytosis(37). Cholesterol is an  
474 essential constituent of functional domains on the membrane, including lipid rafts and  
475 caveolae(40, 41). Cholesterol is required for the formation of endocytic vesicle budding  
476 and membrane ruffling(38, 39).

477 Exosome entry was inhibited by CPZ or CHC knockdown. The rapid accumulation of  
478 exosomes and transferrin in the same transport intermediates affirmed that CME plays a  
479 role in early exosome uptake by hepatocytes. However, CAV1 knockdown had no effect  
480 on exosome internalization. Considering the low expression of CAV1 in HepG2 cells and  
481 primary hepatocytes(52), caveolae-mediated endocytosis may contribute little to  
482 exosome uptake by hepatocytes.

483 Furthermore, we found that EIPA, the hallmark inhibitor of macropinocytosis,  
484 blocked macrophage exosome entry into hepatocytes. The dependence of exosome  
485 entry on PAK1 and PKC was also validated based on the decreased internalization  
486 caused by the corresponding kinase inhibitors. In addition, the increasing colocalization  
487 of exosomes with dextran during exosome uptake implied that macropinocytosis serves  
488 as an efficient alternative route for sustained exosome entry. However, Rac1 and Cdc42,  
489 two Rho GTPases that are usually engaged in macropinocytosis, do not appear to be  
490 involved in macrophage exosome uptake by hepatocytes. This finding is inconsistent  
491 with the interference of exosome entry by EIPA, which inhibits the activation of Rac1 and  
492 Cdc42 by altering the sub-membranous pH(42). Therefore, exosome entry into  
493 hepatocytes may rely on undefined EIPA-sensitive Rho GTPases. Moreover, Rac1- and



494 Cdc42-independent macropinocytosis is reportedly invoked during influenza A virus (IAV)  
495 entry(53). Related studies also showed that circular ruffling and macropinocytosis  
496 independent of Rac1 or Cdc42 could be triggered by the non-receptor tyrosine kinase  
497 c-src(54). The inhibition of CME or macropinocytosis attenuated exosome-mediated  
498 IFN- $\alpha$ -induced anti-HBV transmission, which indicates that exosomes derived from  
499 IFN- $\alpha$ -stimulated macrophages utilize both endocytic mechanisms to deliver HBV  
500 resistance to HBV-replicating hepatocytes.

501 Little research to date has focused on the fates of exosomes and exosomal cargo  
502 after internalization(9). Endocytosed substances are usually directed to the endosomal  
503 system, where they are sorted, processed, recycled, stored and degraded(41). The  
504 endosome system is primarily composed of EEs, recycling endosomes (REs), LEs and  
505 lysosomes(41). LEs often take the form of MVBs. Invagination and inward budding of the  
506 limiting membrane of LEs form ILVs (exosomes) within MVBs(55). Viruses and delivery  
507 vectors exploit endosomes for penetration into the cytosol through membrane fusion to  
508 deliver viral genomes or biologics(44-46).

509 Using a live cell imaging system and a fusion probe (R18), we found that LEs/MVBs  
510 were also the potential site of exosome fusion initiation, followed by cargo uncoating.  
511 Notably, the persistence of R18 dequenching signals for several minutes indicated that  
512 exosome fusion was trapped in an endosomal sub-compartment, identical to the  
513 colocalization of fusion signals with an ILV marker (CD63) (Fig. 5C and D)(27).

514 Previous studies have shown that a high concentration of anionic lipids in LEs  
515 provides an appropriate environment for endosome penetration(46, 56). It was reported

516 that the presence of anionic lipids in the target membrane promoted membrane fusion  
517 efficiency for some enveloped viruses(43, 47, 57). LBPA is a specific anionic lipid in LEs  
518 and is thought to promote ILV budding and back-fusion(55, 58) during MVB biogenesis.  
519 Research has suggested that the vesicular stomatitis virus (VSV) loads nucleocapsids  
520 into ILVs through membrane fusion and penetrates LEs/MVBs through LBPA-dependent  
521 back-fusion between the ILV membrane and the endosome-limiting membrane(43). In  
522 addition, LBPA is also required for efficient cytosolic access of delivery vectors, including  
523 dTAT and phosphorothioate-modified antisense oligonucleotides (PS-ASO)(44, 45).

524 Our results showed that the fusion sites of exosomes were colocalized with LBPA.  
525 Moreover, LBPA antibodies inhibited the membrane fusion of endocytosed exosomes  
526 and accelerated the transport of exosomal cargo to lysosomes. It is possible that some  
527 exosomal cargo may avoid lysosomal degradation via LBPA-dependent membrane  
528 fusion in LEs/MVBs. Given the above results, we hypothesize that LBPA facilitated the  
529 fusion of exosomes from IFN- $\alpha$ -stimulated macrophages with ILVs in LEs/MVBs and that  
530 exosomal antiviral cargo are then reloaded into fused ILVs and released after  
531 back-fusion with the limiting membrane of LEs/MVBs. As former ILVs formed in  
532 LEs/MVBs, endocytosed exosomes with ILV properties may also be qualified for direct  
533 fusion with the limiting membrane of LEs/MVBs to release cargo.

534 Overall, our results illustrate how receptors, endocytic pathways and  
535 LBPA-dependent membrane fusion are exploited by macrophage exosomes to deliver  
536 IFN- $\alpha$ -induced anti-HBV activities to hepatocytes. This study also highlights the overlap  
537 between viruses and exosomes by identifying that the infection strategies of viruses are

538 also applied for exosome entry and exosomal cargo delivery. Dissecting the complete  
539 endocytic routes of exosomes may provide a fundamental basis for engineering  
540 exosomes as therapeutic vehicles to deliver antiviral molecules with high efficiency.

541

## 542 **Acknowledgments**

543 We thank Zhigang Yi, Xiaonan Zhang for valuable comments and suggestions, and Lu  
544 Bai, Xiaoting Du, Yaming Li, Ke Qiao, Shuhui Sun for technical assistance.

545 This work was supported by research grants from the National Natural Science  
546 Foundation of China (81471932), the National Natural Science Foundation (91542207),  
547 the National Key Research and Development Program of China (2016YFC1200400) and  
548 Shanghai Rising-Star Program (14QA1400700).

549 The authors declare no competing financial interests.

550

## 551 **References**

- 552 1. **Block TM, Guo H, Guo J-T.** Molecular Virology of Hepatitis B Virus for Clinicians. Clinics in  
553 Liver Disease **11**:685-706.
- 554 2. **Shepard CW, Simard Ep Fau - Finelli L, Finelli L Fau - Fiore AE, Fiore Ae Fau - Bell BP, Bell BP.**  
555 Hepatitis B virus infection: epidemiology and vaccination.
- 556 3. **Levrero M, Zucman-Rossi J.** 2016. Mechanisms of HBV-induced hepatocellular carcinoma.  
557 Journal of Hepatology **64**:S84-S101.
- 558 4. **Loggi E, Vitale G, Conti F, Bernardi M, Andreone P.** 2015. Chronic hepatitis B: Are we close  
559 to a cure? Dig Liver Dis **47**:836-841.
- 560 5. **Mutz P, Metz P, Lempp FA, Bender S, Qu B, Schoneweis K, Seitz S, Tu T, Restuccia A,**  
561 **Frankish J, Dachert C, Schusser B, Koschny R, Polychronidis G, Schemmer P, Hoffmann K,**  
562 **Baumert TF, Binder M, Urban S, Bartenschlager R.** HBV Bypasses the Innate Immune  
563 Response and Does not Protect HCV From Antiviral Activity of Interferon. LID -  
564 S0016-5085(18)30112-4 [pii] LID - 10.1053/j.gastro.2018.01.044 [doi].

- 565 6. **Suslov A, Boldanova T, Wang X, Wieland S, Heim MH.** Hepatitis B Virus Does Not Interfere  
566 with Innate Immune Responses in the Human Liver. LID - S0016-5085(18)30078-7 [pii] LID -  
567 10.1053/j.gastro.2018.01.034 [doi].
- 568 7. **Li J, Liu K, Liu Y, Xu Y, Zhang F, Yang H, Liu J, Pan T, Chen J, Wu M, Zhou X, Yuan Z.** 2013.  
569 Exosomes mediate the cell-to-cell transmission of IFN-alpha-induced antiviral activity. *Nat*  
570 *Immunol* **14**:793-803.
- 571 8. **Giugliano S, Kriss M, Golden-Mason L, Dobrinskikh E, Stone AEL, Soto-Gutierrez A,**  
572 **Mitchell A, Khetani SR, Yamane D, Stoddard M, Li H, Shaw GM, Edwards MG, Lemon SM,**  
573 **Gale M, Shah VH, Rosen HR.** 2015. HCV Infection Induces Autocrine Interferon Signaling by  
574 Human Liver Endothelial Cell and Release of Exosomes, Which Inhibits Viral Replication.  
575 *Gastroenterology* **148**:392-402.e313.
- 576 9. **van Dongen HM, Masoumi N, Witwer KW, Pegtel DM.** 2016. Extracellular Vesicles Exploit  
577 Viral Entry Routes for Cargo Delivery. *Microbiol Mol Biol Rev* **80**:369-386.
- 578 10. **Klenerman P, Ramamurthy N.** Liver sinusoidal endothelial cells: an antiviral  
579 "defendothelium".
- 580 11. **Bordon Y.** Viral immunity: arms convoy.
- 581 12. **Thery C, Ostrowski M, Segura E.** 2009. Membrane vesicles as conveyors of immune  
582 responses. *Nat Rev Immunol* **9**:581-593.
- 583 13. **Izquierdo-Useros N, Puertas MC, Borrás FE, Blanco J, Martínez-Picado J.** 2011. Exosomes  
584 and retroviruses: the chicken or the egg? *Cell Microbiol* **13**:10-17.
- 585 14. **Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES,**  
586 **Lindenberg JL, de Gruijl TD, Wurdinger T, Middeldorp JM.** 2010. Functional delivery of viral  
587 miRNAs via exosomes. *Proc Natl Acad Sci U S A* **107**:6328-6333.
- 588 15. **Schorey JS, Bhatnagar S.** 2008. Exosome function: from tumor immunology to pathogen  
589 biology. *Traffic* **9**:871-881.
- 590 16. **Robbins PD, Morelli AE.** 2014. Regulation of Immune Responses by Extracellular Vesicles.  
591 *Nature reviews Immunology* **14**:195-208.
- 592 17. **Lai RC, Yeo RW, Tan KH, Lim SK.** 2013. Exosomes for drug delivery - a novel application for  
593 the mesenchymal stem cell. *Biotechnol Adv* **31**:543-551.
- 594 18. **van den Boorn JG, Schlee M, Coch C, Hartmann G.** 2011. siRNA delivery with exosome  
595 nanoparticles. *Nature Biotechnology* **29**:325.
- 596 19. **Wei X, Liu C, Wang H, Wang L, Xiao F, Guo Z, Zhang H.** 2016. Surface Phosphatidylserine Is  
597 Responsible for the Internalization on Microvesicles Derived from Hypoxia-Induced Human  
598 Bone Marrow Mesenchymal Stem Cells into Human Endothelial Cells. *PLoS One*  
599 **11**:e0147360.
- 600 20. **Morelli AE, Larregina AT, Shufesky WJ, Sullivan ML, Stolz DB, Papworth GD, Zahorchak AF,**  
601 **Logar AJ, Wang Z, Watkins SC, Falo LD, Jr., Thomson AW.** 2004. Endocytosis, intracellular  
602 sorting, and processing of exosomes by dendritic cells. *Blood* **104**:3257-3266.
- 603 21. **Christianson HC, Svensson KJ, Fau - van Kuppevelt TH, van Kuppevelt Th Fau - Li J-P, Li Jp**  
604 **Fau - Belting M, Belting M.** Cancer cell exosomes depend on cell-surface heparan sulfate  
605 proteoglycans for their internalization and functional activity. doi:D - NLM: PMC3808637  
606 OTO - NOTNLM.
- 607 22. **Tian T, Zhu YL, Zhou YY, Liang GF, Wang YY, Hu FH, Xiao ZD.** 2014. Exosome uptake through  
608 clathrin-mediated endocytosis and macropinocytosis and mediating miR-21 delivery. *J Biol*

- 609 Chem **289**:22258-22267.
- 610 23. **Nanbo A, Kawanishi E, Yoshida R, Yoshiyama H.** 2013. Exosomes derived from Epstein-Barr  
611 virus-infected cells are internalized via caveola-dependent endocytosis and promote  
612 phenotypic modulation in target cells. *J Virol* **87**:10334-10347.
- 613 24. **Li J, Lin S Fau - Chen Q, Chen Q Fau - Peng L, Peng L Fau - Zhai J, Zhai J Fau - Liu Y, Liu Y Fau**  
614 **- Yuan Z, Yuan Z.** Inhibition of hepatitis B virus replication by MyD88 involves accelerated  
615 degradation of pregenomic RNA and nuclear retention of pre-S/S RNAs. doi:D - NLM:  
616 PMC2903248 EDAT- 2010/04/23 06:00 MHDA- 2010/06/30 06:00 CRDT- 2010/04/23 06:00  
617 PHST- 2010/04/23 06:00 [entrez] PHST- 2010/04/23 06:00 [pubmed] PHST- 2010/06/30  
618 06:00 [medline] AID - JVI.00236-10 [pii] AID - 10.1128/JVI.00236-10 [doi] PST - ppublish.
- 619 25. **Auwerx J.** The human leukemia cell line, THP-1: a multifaceted model for the study of  
620 monocyte-macrophage differentiation.
- 621 26. **Sherer NM, Lehmann MJ, Jimenez-Soto LF, Ingmundson A, Horner SM, Cicchetti G, Allen**  
622 **PG, Pypaert M, Cunningham JM, Mothes W.** 2003. Visualization of retroviral replication in  
623 living cells reveals budding into multivesicular bodies. *Traffic* **4**:785-801.
- 624 27. **Nour AM, Li Y, Wolenski J, Modis Y.** 2013. Viral membrane fusion and nucleocapsid delivery  
625 into the cytoplasm are distinct events in some flaviviruses. *PLoS Pathog* **9**:e1003585.
- 626 28. **Citovsky V Fau - Blumenthal R, Blumenthal R Fau - Loyter A, Loyter A.** Fusion of Sendai  
627 virions with phosphatidylcholine-cholesterol liposomes reflects the viral activity required for  
628 fusion with biological membranes.
- 629 29. **L Barlow A, Macleod A, Noppen S, Sanderson J, J Guérin C.** 2010. Colocalization Analysis in  
630 Fluorescence Micrographs: Verification of a More Accurate Calculation of Pearson's  
631 Correlation Coefficient, vol 16.
- 632 30. **Fitzner D, Schnaars M, van Rossum D, Krishnamoorthy G, Dibaj P, Bakhti M, Regen T,**  
633 **Hanisch UK, Simons M.** 2011. Selective transfer of exosomes from oligodendrocytes to  
634 microglia by macropinocytosis. *J Cell Sci* **124**:447-458.
- 635 31. **Amara A, Mercer J.** 2015. Viral apoptotic mimicry. *Nature Reviews Microbiology*  
636 **13**:461-469.
- 637 32. **Moller-Tank S, Albritton LM, Rennert PD, Maury W.** Characterizing functional domains for  
638 TIM-mediated enveloped virus entry.
- 639 33. **Mulcahy LA, Pink RC, Carter DR.** 2014. Routes and mechanisms of extracellular vesicle  
640 uptake. *J Extracell Vesicles* **3**.
- 641 34. **Doherty GJ, McMahon HT.** 2009. Mechanisms of endocytosis. *Annu Rev Biochem*  
642 **78**:857-902.
- 643 35. **Nonnenmacher M, Weber T.** 2011. Adeno-associated virus 2 infection requires endocytosis  
644 through the CLIC/GEEC pathway. *Cell Host Microbe* **10**:563-576.
- 645 36. **Antonny B, Burd C, De Camilli P, Chen E, Daumke O, Faelber K, Ford M, Frolov VA, Frost A,**  
646 **Hinshaw JE, Kirchhausen T, Kozlov MM, Lenz M, Low HH, McMahon H, Merrifield C,**  
647 **Pollard TD, Robinson PJ, Roux A, Schmid S.** 2016. Membrane fission by dynamin: what we  
648 know and what we need to know. *The EMBO Journal* **35**:2270-2284.
- 649 37. **Mercer J, Helenius A.** 2012. Gulping rather than sipping: macropinocytosis as a way of virus  
650 entry. *Curr Opin Microbiol* **15**:490-499.
- 651 38. **Subtil A, Gaidarov I Fau - Kobylarz K, Kobylarz K Fau - Lampson MA, Lampson Ma Fau -**  
652 **Keen JH, Keen Jh Fau - McGraw TE, McGraw TE.** Acute cholesterol depletion inhibits

- 653 clathrin-coated pit budding. doi:D - NLM: PMC21991 EDAT- 1999/06/09 00:00 MHDA-  
654 1999/06/09 00:01 CRDT- 1999/06/09 00:00 PHST- 1999/06/09 00:00 [pubmed] PHST-  
655 1999/06/09 00:01 [medline] PHST- 1999/06/09 00:00 [entrez] PST - ppublish.
- 656 39. **Mercer J, Helenius A.** 2009. Virus entry by macropinocytosis. *Nat Cell Biol* **11**:510-520.
- 657 40. **Branza-Nichita N, Macovei A, Lazar C.** 2012. Caveolae-Dependent Endocytosis in Viral  
658 Infection. doi:10.5772/48538.
- 659 41. **Mercer J, Schelhaas M, Helenius A.** 2010. Virus entry by endocytosis. *Annu Rev Biochem*  
660 **79**:803-833.
- 661 42. **Koivusalo M, Welch C, Hayashi H, Scott CC, Kim M, Alexander T, Touret N, Hahn KM,**  
662 **Grinstein S.** 2010. Amiloride inhibits macropinocytosis by lowering submembranous pH and  
663 preventing Rac1 and Cdc42 signaling. *The Journal of Cell Biology* **188**:547-563.
- 664 43. **Le Blanc I, Luyet PP, Pons V, Ferguson C, Emans N, Petiot A, Mayran N, Demaurex N, Faure**  
665 **J, Sadoul R, Parton RG, Gruenberg J.** 2005. Endosome-to-cytosol transport of viral  
666 nucleocapsids. *Nat Cell Biol* **7**:653-664.
- 667 44. **Erazo-Oliveras A, Najjar K, Truong D, Wang TY, Brock DJ, Prater AR, Pellois JP.** 2016. The  
668 Late Endosome and Its Lipid BMP Act as Gateways for Efficient Cytosolic Access of the  
669 Delivery Agent dTAT and Its Macromolecular Cargos. *Cell Chem Biol* **23**:598-607.
- 670 45. **Wang S, Sun H, Tanowitz M, Liang X-h, Crooke ST.** 2017. Intra-endosomal trafficking  
671 mediated by lysobisphosphatidic acid contributes to intracellular release of  
672 phosphorothioate-modified antisense oligonucleotides. *Nucleic Acids Research*  
673 **45**:5309-5322.
- 674 46. **White JM, Whittaker GR.** 2016. Fusion of Enveloped Viruses in Endosomes. *Traffic*  
675 **17**:593-614.
- 676 47. **Roth SL, Whittaker GR.** 2011. Promotion of vesicular stomatitis virus fusion by the  
677 endosome-specific phospholipid bis(monoacylglycero)phosphate (BMP). *FEBS Letters*  
678 **585**:865-869.
- 679 48. **Farzan M, Pasqual G, Rojek JM, Masin M, Chatton J-Y, Kunz S.** 2011. Old World  
680 Arenaviruses Enter the Host Cell via the Multivesicular Body and Depend on the Endosomal  
681 Sorting Complex Required for Transport. *PLoS Pathogens* **7**:e1002232.
- 682 49. **Thery C, Zitvogel L, Amigorena S, Amigorena S.** Exosomes: composition, biogenesis  
683 and function.
- 684 50. **Kaplan G, Totsuka A, Thompson P, Akatsuka T, Moritsugu Y, Feinstone SM.** 1996.  
685 Identification of a surface glycoprotein on African green monkey kidney cells as a receptor  
686 for hepatitis A virus. *Embo j* **15**:4282-4296.
- 687 51. **Ramakrishnaiah V, van der Laan LJW.** 2014. Hepatitis virus hijacks shuttle: Exosome-like  
688 vesicles provide protection against neutralizing antibodies. *Hepatology* **59**:2416-2418.
- 689 52. **Cokakli M, Erdal E, Nart D, Yilmaz F, Sagol O, Kilic M, Karademir S, Atabey N.** 2009.  
690 Differential expression of Caveolin-1 in hepatocellular carcinoma: correlation with  
691 differentiation state, motility and invasion. *BMC Cancer* **9**:65.
- 692 53. **Pekosz A, de Vries E, Tscherne DM, Wienholts MJ, Cobos-Jiménez V, Scholte F,**  
693 **García-Sastre A, Rottier PJM, de Haan CAM.** 2011. Dissection of the Influenza A Virus  
694 Endocytic Routes Reveals Macropinocytosis as an Alternative Entry Pathway. *PLoS*  
695 *Pathogens* **7**:e1001329.
- 696 54. **Mettlen M, Platek A, Van Der Smissen P, Van Der Smissen P, Carpentier S,**

697 **Carpentier S Fau - Amyere M, Amyere M Fau - Lanzetti L, Lanzetti L Fau - de Diesbach P, de**  
698 **Diesbach P Fau - Tyteca D, Tyteca D Fau - Courtoy PJ, Courtoy PJ.** Src triggers circular  
699 ruffling and macropinocytosis at the apical surface of polarized MDCK cells.  
700 55. **Piper RC, Katzmann DJ.** 2007. Biogenesis and function of multivesicular bodies. *Annu Rev*  
701 *Cell Dev Biol* **23**:519-547.  
702 56. **Matos PM, Marin M, Ahn B, Lam W, Santos NC, Melikyan GB.** 2013. Anionic lipids are  
703 required for vesicular stomatitis virus G protein-mediated single particle fusion with  
704 supported lipid bilayers. *J Biol Chem* **288**:12416-12425.  
705 57. **Zaitseva E, Yang ST, Melikov K, Pourmal S, Chernomordik LV.** 2010. Dengue virus ensures its  
706 fusion in late endosomes using compartment-specific lipids. *PLoS Pathog* **6**:e1001131.  
707 58. **Matsuo H, Chevallier J Fau - Mayran N, Mayran N Fau - Le Blanc I, Le Blanc I Fau - Ferguson**  
708 **C, Ferguson C Fau - Faure J, Faure J Fau - Blanc NS, Blanc Ns Fau - Matile S, Matile S Fau -**  
709 **Dubochet J, Dubochet J Fau - Sadoul R, Sadoul R Fau - Parton RG, Parton Rg Fau - Vilbois F,**  
710 **Vilbois F Fau - Gruenberg J, Gruenberg J.** Role of LBPA and Alix in multivesicular liposome  
711 formation and endosome organization.

712

## 713 **Figure legends**

714 **Figure 1. TIM-1 mediates exosome internalization and IFN- $\alpha$ -induced anti-HBV**  
715 **activity transmission.**

716 **(A)** Electron microscopy of purified exosomes from macrophages. Scale bar: 100 nm.

717 **(B)** Immunoblot analysis of macrophage-derived exosomes (left) and corresponding  
718 cells (right) for exosomal and non exosomal markers.

719 **(C)** PKH26-labeled exosome internalization by HepG2 cells. Scale bar: 5  $\mu$ m.

720 **(D)** Time- and concentration-dependent uptake of exosomes. HepG2 cells were  
721 incubated with PKH67-labeled exosomes (PKH67-EXO) at the indicated concentrations  
722 for up to 10 h (right). The fluorescence intensity distribution of cells incubated with  
723 PKH67-EXO for 3 h is also shown (left).

724 **(E)** PtdSer detection on the exosome surface. Exosomes coated onto 4  $\mu$ m latex beads  
725 were either stained or not with Annexin V-FITC and analyzed by flow cytometry.

726 **(F)** Knockdown validation of TIM-1 by immunoblot.

727 **(G, H)** Confocal images (G) or flow cytometry analysis (H) of PKH26-labeled exosome  
728 internalization by HepG2 cells after TIM-1 knockdown. Scale bars: 10  $\mu$ m. For flow  
729 cytometry analysis, both histogram graph (left) and mean fluorescence intensities (MFI)  
730 (right) which are normalized to siCTRL-transfected cells are presented.

731 **(I)** Flow cytometry analysis of PKH26-labeled exosome internalization by HepG2 cells  
732 in presence or absence (Ctrl) of Fc-TIM-1-His. MFI (right) are normalized to ctrl cells.

733 **(J, K)** Blockade of IFN- $\alpha$ -induced anti-HBV activity transmission by TIM-1 knockdown.  
734 HepG2.2.15 cells transfected with either siTIM-1 or siCTRL were treated with exosomes  
735 from IFN- $\alpha$ -stimulated macrophages (IFN-EXO) or unstimulated cells (Ctrl-EXO). HBsAg  
736 and HBV DNA levels in the medium were measured by ELISA (J) or quantified by qPCR  
737 (K).

738 The error bars indicate the SD. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$   
739 (Student's t-test). The data are representative of three independent experiments.

740 **Figure 2. Exosome internalization is dynamin- and cholesterol-dependent.**

741 **(A)** Schematic representation of the roles of dynamin-2 and cholesterol in various  
742 endocytic pathways.

743 **(B, C)** Confocal images (B) or flow cytometry analysis (C) of exosome and transferrin  
744 internalization by HepG2 cells treated with dynasore. Scale bars: 10  $\mu$ m. MFI (right) are  
745 normalized to DMSO-treated cells.

746 **(D)** Flow cytometry analysis of exosome internalization by HepG2 cells transfected with  
747 EGFP-Dyn2K44A mutant. HepG2 cells transfected with EGFP-tagged



748 dominant-negative dynK44A mutant were incubated with PKH26-labeled exosomes.  
749 Transfected cells (EGFP+) are gated, and the uptake of exosomes among transfected  
750 cells (EGFP+/PKH26+) is analyzed and presented by histogram graph (left) and MFI  
751 (right). MFI are normalized to vector-transfected controls.

752 **(E-H)** Confocal images (E) or flow cytometry analysis (F-H) of exosome internalization  
753 by HepG2 cells treated with cholesterol inhibitors (M $\beta$ CD, Nystatin and Filipin). Scale  
754 bars: 10  $\mu$ m. For flow cytometry analysis, MFI (right) are normalized to DMSO-treated  
755 cells.

756 The error bars indicate the SD. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  (Student's t-test). The  
757 data are representative of three independent experiments.

758 **Figure 3. Exosome internalization involves clathrin-mediated endocytosis (CME)**  
759 **not caveolae-mediated endocytosis.**

760 **(A, B)** Confocal images (A) or flow cytometry analysis (B) of exosome and transferrin  
761 internalization by HepG2 cells treated with 10  $\mu$ g/ml CPZ. Scale bars: 10  $\mu$ m. For flow  
762 cytometry analysis, MFI (right) are normalized to DMSO-treated cells.

763 **(C)** Knockdown validation of clathrin heavy chain (CHC) by immunoblot.

764 **(D)** Flow cytometry analysis of exosome internalization by HepG2 cells after CHC  
765 knockdown. MFI (right) are normalized to siCTRL-transfected cells.

766 **(E, F)** Internalized exosome colocalized with transferrin 30 (E) min or 1 h (F) after  
767 internalization. The cells were fixed and analyzed by confocal microscopy. Scatterplots  
768 and Pearson's correlation coefficients for the overlap of red (Alexa568-transferrins) and  
769 green (PKH67-labeled exosomes) pixel intensities corresponding to the images are

770 presented. Intensity profiles are used to describe the distribution along the indicated

771 white arrow in the region of interest (ROI). Scale bars: 5  $\mu$ m.

772 **(G, H)** Blockade of IFN- $\alpha$ -induced anti-HBV activity transmission by CHC knockdown.

773 HepG2.2.15 cells transfected with either siCHC or siCTRL were treated with IFN-EXO or

774 Ctrl-EXO. HBsAg and HBV DNA levels in the medium were measured by ELISA (G) or

775 quantified by qPCR (H).

776 **I** Knockdown validation of caveolin-1 (CAV1) by immunoblot. Endogenous amount of

777 caveolin-1 in HepG2 cells is low. To test the knock-down efficiency, siRNAs with a

778 plasmid encoding EGFP-CAV1 were cotransfected. Expression of EGFP-CAV1 was

779 assessed by immunoblot.

780 **J** Flow cytometry analysis of exosome internalization by HepG2 cells with CAV1

781 knocked down. MFI (right) are normalized to siCTRL-transfected cells.

782 The error bars indicate the SD. \* $P < 0.05$ , \*\*\*\* $P < 0.0001$  (Student's t-test). The data are

783 representative of three independent experiments.

784 **Figure 4. Exosome internalization involves macropinocytosis.**

785 **(A)** Preincubation with exosomes increased dextran uptake in HepG2 cells.

786 RhoB-dextran (RhoB-DEX) uptake by HepG2 cells pretreated with exosomes (EXO(+))

787 was analyzed by flow cytometry, and the MFI is normalized to untreated cells (EXO(-)).

788 **(B, C)** Confocal images (B) or flow cytometry analysis (C) of exosome and dextran

789 internalization by HepG2 cells treated with EIPA. Scale bars: 10  $\mu$ m. For flow cytometry

790 analysis, MFI (right) are normalized to DMSO-treated cells.

791 **(D-F)** Confocal images (D) or flow cytometry analysis (E, F) of exosome and dextran

792 internalization by HepG2 cells treated with IPA-3 or rottlerin. Scale bars: 10  $\mu$ m. For flow  
793 cytometry analysis, MFI (right) are normalized to DMSO-treated cells.

794 **(G, H)** Exosome uptake is independent of Rac1 or Cdc42. Flow cytometry analysis of  
795 exosome internalization by HepG2 cells transfected with EGFP-Rac1 DN mutant (G) or  
796 EGFP-Cdc42 DN mutant (H), followed by the incubation with PKH26-labeled exosomes.  
797 Transfected cells (EGFP+) are gated, and the uptake of exosomes among transfected  
798 cells (EGFP+/PKH26+) is analyzed as described above.

799 **(I, J)** Internalized exosome colocalized with dextran 30 min (I) or 1 h (J) after  
800 internalization. The colocalization of Rho-dextran (red) with PKH67-labeled exosomes  
801 (green) is analyzed as described above. Scale bars: 5  $\mu$ m.

802 **(K)** Blockade of IFN- $\alpha$ -induced anti-HBV activity transmission by EIPA treatment.  
803 HepG2.2.15 cells were pretreated with DMSO or EIPA which presented continuously  
804 during following incubation with IFN-EXO or Ctrl-EXO. HBV DNA levels in the medium  
805 were quantified by qPCR.

806 The error bars indicate the SD. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\*\* $P < 0.0001$  (Student's t-test).

807 The data are representative of three independent experiments.

808 **Figure 5. Membrane fusion of GFP-carrying exosomes occurs in LEs/MVBs.**

809 **(A)** Hypothesized model of exosome fusion and cargo release in endosomes.

810 **(B)** Images of R18 dequenching triggered by exosome membrane fusion.  
811 R18-dequenching fusion spots (red) were tracked and imaged at the indicated time  
812 points via time-lapse microscopy. Scale bars: 5  $\mu$ m.

813 **(C)** Time-intensity profiles of R18 fluorescence of two representative dequenching

814 spots in experiment (B).

815 **(D)** Membrane fusion signals of exosomes colocalized with the LE marker CFP-RAB7  
816 and the ILV marker CFP-CD63. Dynamic colocalization events of dequenching signals  
817 (red) with cellular markers (CFP pseudo-colored green) were tracked via time-lapse  
818 microscopy. Scatterplots and Pearson's correlation coefficients for colocalization are  
819 presented below the images. Scale bars: 5  $\mu\text{m}$ .

820 **(E)** Color shift induced by ongoing fusion process of GFP-carrying exosomes  
821 prelabeled with self-quenching concentrations of R18 was observed and imaged via  
822 time-lapse microscopy. Scale bars: 5  $\mu\text{m}$ .

823 **(F)** Membrane fusion signals of GFP-carrying exosomes colocalized with the LE  
824 marker RAB7. Scatterplots and Pearson's correlation coefficient between the signals of  
825 GFP and R18 or the signals of R18 and RAB7 are presented. Fluorescence intensity  
826 profiles of GFP, RAB7 and R18 along the indicated white arrow in the ROI are also  
827 presented. Scale bars: 10  $\mu\text{m}$ .

828 **Figure 6. LBPA is required for exosome fusion and cargo uncoating.**

829 **(A)** Accumulation of PKH26-labeled exosomes in LBPA-rich vacuoles. Colocalization  
830 of PKH26 (red) with LBPA (green) is analyzed as mentioned above. Scale bar: 10  $\mu\text{m}$ .

831 **(B)** Membrane fusion signals of dequenching R18-exosomes colocalized with LBPA.  
832 Colocalization of dequenching signals (red) with LBPA (green) is analyzed as described  
833 above. Scale bars: 10  $\mu\text{m}$ .

834 **(C)** Inhibition of exosome fusion by antibodies against LBPA. Fusion spots of  
835 dequenching R18-exosomes in HepG2 cells pretreated with 50  $\mu\text{g/ml}$  anti-LBPA or

836 anti-IgG overnight were tracked and photographed at the indicated time points. Scale  
837 bars: 5  $\mu$ m.

838 **(D)** Time-intensity profiles of R18 fluorescence of four representative dequenching  
839 spots in experiment (C).


840 **(E)** Increase in colocalization of the exosomal cargo GFP with lysosomes after  
841 exposure to antibodies against LBPA. HepG2 cells pretreated with anti-LBPA or anti-IgG  
842 overnight were incubated with GFP-carrying exosomes in the presence of Lyso Tracker.  
843 Colocalization of GFP (green) with lysosomes (red) is analyzed via scatterplots and  
844 Pearson's correlation coefficients. Scale bars: 10  $\mu$ m.

845 **Figure 7. Proposed model of exosome entry and delivery of IFN- $\alpha$ -induced HBV**  
846 **resistance.**

847 After binding to TIM-1, exosomes from IFN- $\alpha$ -stimulated macrophages enter  
848 HBV-replicating hepatocytes through CME (rapid mode) and macropinocytosis  
849 (sustained mode). Endocytosed exosomes traffic to LEs/MVBs and fuse with LBPA-rich  
850 ILVs. Trapped antiviral cargo in the ILVs are released to the cytosol via the back-fusion of  
851 ILVs with the limiting membrane of LEs/MVBs (violet arrow). Alternatively, ILV-derived  
852 exosomes release antiviral cargo via direct fusion with LEs/MVBs (blue arrow).


853

# Figure 1




# Figure 2


**A**




**B**




**C**




**D**




**E**




**F**



**G**




**H**






# Figure 3


**A**





**B**





**C**




**D**




**E**




**F**




**G**





**H**



**I**




**J**






# Figure 4


**A**




**B**




**D**




**C**




**G**




**E**




**H**




**F**




**K**




**I**




**J**



# Figure 5



# Figure 6



**Figure 7**

